United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Size was valued at USD 40.5 Billion in 2022. The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market industry is projected to grow from USD 44.63 Billion in 2023 to USD 97.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032). Modern manufacturing methods and procedures, the expansion of the market for generic medications, and the significant use of small molecule medications for a variety of illnesses are the main market drivers expected to drive the United States industry for pharmaceutical contract development and manufacturing organizations (CDMOs).
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Pharmaceutical businesses are being encouraged to launch efficient pharmaceutical solutions to speed up the treatment process for the rising incidence of chronic diseases and the aging population in the US. The World Health Organization (WHO) predicts that by 2020, non-communicable diseases (NCDs) will account for 57% of the burden of disease. Additionally, the ability of CDMOs to streamline the pharmaceutical supply chain and the implementation of the one-stop-shop concept to introduce efficient drug goods into the market is anticipated to fuel the expansion of the CDMO market in the United States over the projected period. In the upcoming years, it is expected that the CDMO market CAGR will grow more rapidly in the United States due to the expanding therapeutic applications of biologics and the growing share of pipeline compounds.
In addition, the growth of the contract development and manufacturing organizations sector is anticipated to be fueled by rising infrastructure expenditures and the ability of United States CDMOs to offer completely integrated services through cutting-edge technologies. Due to the availability of cutting-edge R&D & production platforms and trained workers, the outsourcing of manufacturing processes to CDMOs has also resulted in rapid regulatory clearances in the United States. A lot of CDMOs are putting a lot of effort into capital investments in order to diversify geographically and create new compounds. October 2017 saw the announcement by CordenPharma International of a strategic €3.7 million investment in their Swiss small molecule API production facility. Additionally, one of the main factors expected to drive the expansion of the CDMO market throughout the projected period is the augmentation of the number of new entrants via partnerships.
The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on Service, includes Pharmaceutical Manufacturing Services, Drug Development Services, and Biologics Manufacturing Services. The pharmaceutical manufacturing services segment held a substantial stake, which may be attributable to factors including the growing demand for biologics and biosimilars in the region, as well as the expanding pharmaceutical and biopharmaceutical industries worldwide. Additionally, major industry participants are spending money on drug development and discovery, which is expected to fuel the segment's expansion.
Figure 1: United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, by Service, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on End User, includes Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma, and Other End Users. Throughout the projection period, the big pharma category is anticipated to have the highest CAGR. Some of the key factors expected to propel the market's growth are increased investment in the big pharma firms of gene and cell therapies, a rise in the number of biologics undergoing pipeline investigations, and the growing demand for targeted medication therapy.
For small and mid-sized pharmaceutical companies, the process of finding and developing new drugs is extremely costly and time-consuming. Nonetheless, drug development activities are outsourced to contract development and research groups by pharmaceutical companies, who choose this more cost-effective and efficient approach in the US. Serious repercussions are incurred by the company, and the brand name when guidelines and regulations are not followed by the appropriate authorities and defective pharmaceuticals are produced. As a result, in the pharmaceutical sector, following regulatory requirements is crucial. Major pharmaceutical corporations in the United States are also restocking the market with increased investments in this area. In order to satisfy market and outsourcing demand, the United States contract manufacturing organizations, or CMOs, have expanded from their original provision of basic manufacturing services to a broad package of services.
Leading market players are putting more on R&D to increase the range of products they offer, which will support the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market's expansion. In addition, market players are engaging in a range of calculated initiatives to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry must provide reasonably priced goods.
Major players in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market are engaging in research and development activities in an effort to boost market demand includes Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).
February 2022: Recipharm AB (Sweden) purchased Arranta Bio (U.S.) in order to expand its service offerings and establish a solid foothold in the U.S. by providing scientifically distinct contract research and manufacturing services for ATMPs.
February 2021: Charles River Laboratories International, Inc. (United States) paid $875 million to Cognate BioServices, Inc. (United States) to expand their capabilities in cell and gene therapy CDMOs.
February 2020: MaSTherCell Global Inc. (Belgium) was purchased by Catalent Inc. (U.S.) for $315 million with the intention of utilizing MaSTherCell's distinctive portfolio of technologies, capabilities, and associated analytical services to lead the field with its cell & genetic therapy platforms.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 40.5 Billion |
| Market Size 2023 | USD 44.63 Billion |
| Market Size 2032 | USD 97.07 Billion |
| Compound Annual Growth Rate (CAGR) | 10.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Distribution Channel, and Region |
| Countries Covered | United States |
| Key Companies Profiled | Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany) |
| Key Market Opportunities | ·        High expense of developing drugs in-house is probably going to fuel market expansion. ·        Rising demand for pharmaceutical products will fuel growth. |
| Key Market Dynamics | ·        Increase in strategic alliances and investments to support CDMOs, or contract development and manufacturing organizations ·        Growing biologics therapeutic applications and a larger proportion of pipeline compounds are expected to fuel the CDMO sector's growth in the upcoming years. |
Frequently Asked Questions (FAQ) :
In 2022, the pharmaceutical contract development and manufacturing organization (CDMMO) market in the United States was estimated to be worth USD 40.5 billion.
From 2023 to 2032, the market is expected to expand at a compound annual growth rate (CAGR) of 10.20%.
AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), and Thermo Fisher Scientific Inc. (US) are the major players in the market.
In 2022, the market was dominated by the Pharmaceutical Manufacturing Services segment.
The market share that the Big Pharma category held was the highest.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
